Cargando…

Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway

The initiation of atherosclerosis (AS) induced by dyslipidemia is accompanied by endothelial dysfunction, including decreased healing ability and increased recruitment of monocytes. Studies showed ginsenoside Rg3 has potential to treat diseases associated with endothelial dysfunction which can prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Jianan, Fu, Wenwen, Yu, Xiaofeng, Lu, Zeyuan, Liu, Yanzhe, Sun, Mingyang, Yu, Ping, Li, Xin, Fu, Li, Xu, Huali, Sui, Dayun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188907/
https://www.ncbi.nlm.nih.gov/pubmed/32390845
http://dx.doi.org/10.3389/fphar.2020.00500
_version_ 1783527393905868800
author Geng, Jianan
Fu, Wenwen
Yu, Xiaofeng
Lu, Zeyuan
Liu, Yanzhe
Sun, Mingyang
Yu, Ping
Li, Xin
Fu, Li
Xu, Huali
Sui, Dayun
author_facet Geng, Jianan
Fu, Wenwen
Yu, Xiaofeng
Lu, Zeyuan
Liu, Yanzhe
Sun, Mingyang
Yu, Ping
Li, Xin
Fu, Li
Xu, Huali
Sui, Dayun
author_sort Geng, Jianan
collection PubMed
description The initiation of atherosclerosis (AS) induced by dyslipidemia is accompanied by endothelial dysfunction, including decreased healing ability and increased recruitment of monocytes. Studies showed ginsenoside Rg3 has potential to treat diseases associated with endothelial dysfunction which can protects against antineoplastic drugs induced cardiotoxicity by repairing endothelial function, while the effect and mechanism of Rg3 on dyslipidemia induced endothelial dysfunction and AS are not clear. Therefore, we investigated the effects of Rg3 on oxidized low-density lipoprotein (ox-LDL) induced human umbilical vein endothelial cells (HUVECs) dysfunction and high-fat diets (HFD) induced atherosclerosis in ApoE(−/−) mice, as well as the mechanism. For in vitro assay, Rg3 enhanced healing of HUVECs and inhibited human monocytes (THP-1) adhesion to HUVECs disturbed by ox-LDL, down-regulated focal adhesion kinase (FAK)-mediated expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1); restrained the FAK-mediated non-adherent dependent pathway containing matrix metalloproteinase (MMP)-2/9 expression, activation of nuclear factor-kappa B (NF-κB), high mRNA levels of monocyte chemotactic protein 1 (MCP-1) and interleukin 6 (IL-6), besides Rg3 up-regulated peroxisome proliferators-activated receptor γ (PPARγ) in ox-LDL-stimulated HUVECs. GW9662, the PPARγ-specific inhibitor, can repressed the effects of Rg3 on ox-LDL-stimulated HUVECs. For in vivo assay, Rg3 significantly reduced atherosclerotic pathological changes in ApoE(−/−) mice fed with HFD, up-regulated PPARγ, and inhibited activation FAK in aorta, thus inhibited expression of VCAM-1, ICAM-1 in intima. We conclude that Rg3 may protect endothelial cells and inhibit atherosclerosis by up-regulating PPARγ via repressing FAK-mediated pathways, indicating that Rg3 have good potential in preventing dyslipidemia induced atherosclerosis.
format Online
Article
Text
id pubmed-7188907
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71889072020-05-08 Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway Geng, Jianan Fu, Wenwen Yu, Xiaofeng Lu, Zeyuan Liu, Yanzhe Sun, Mingyang Yu, Ping Li, Xin Fu, Li Xu, Huali Sui, Dayun Front Pharmacol Pharmacology The initiation of atherosclerosis (AS) induced by dyslipidemia is accompanied by endothelial dysfunction, including decreased healing ability and increased recruitment of monocytes. Studies showed ginsenoside Rg3 has potential to treat diseases associated with endothelial dysfunction which can protects against antineoplastic drugs induced cardiotoxicity by repairing endothelial function, while the effect and mechanism of Rg3 on dyslipidemia induced endothelial dysfunction and AS are not clear. Therefore, we investigated the effects of Rg3 on oxidized low-density lipoprotein (ox-LDL) induced human umbilical vein endothelial cells (HUVECs) dysfunction and high-fat diets (HFD) induced atherosclerosis in ApoE(−/−) mice, as well as the mechanism. For in vitro assay, Rg3 enhanced healing of HUVECs and inhibited human monocytes (THP-1) adhesion to HUVECs disturbed by ox-LDL, down-regulated focal adhesion kinase (FAK)-mediated expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1); restrained the FAK-mediated non-adherent dependent pathway containing matrix metalloproteinase (MMP)-2/9 expression, activation of nuclear factor-kappa B (NF-κB), high mRNA levels of monocyte chemotactic protein 1 (MCP-1) and interleukin 6 (IL-6), besides Rg3 up-regulated peroxisome proliferators-activated receptor γ (PPARγ) in ox-LDL-stimulated HUVECs. GW9662, the PPARγ-specific inhibitor, can repressed the effects of Rg3 on ox-LDL-stimulated HUVECs. For in vivo assay, Rg3 significantly reduced atherosclerotic pathological changes in ApoE(−/−) mice fed with HFD, up-regulated PPARγ, and inhibited activation FAK in aorta, thus inhibited expression of VCAM-1, ICAM-1 in intima. We conclude that Rg3 may protect endothelial cells and inhibit atherosclerosis by up-regulating PPARγ via repressing FAK-mediated pathways, indicating that Rg3 have good potential in preventing dyslipidemia induced atherosclerosis. Frontiers Media S.A. 2020-04-22 /pmc/articles/PMC7188907/ /pubmed/32390845 http://dx.doi.org/10.3389/fphar.2020.00500 Text en Copyright © 2020 Geng, Fu, Yu, Lu, Liu, Sun, Yu, Li, Fu, Xu and Sui http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Geng, Jianan
Fu, Wenwen
Yu, Xiaofeng
Lu, Zeyuan
Liu, Yanzhe
Sun, Mingyang
Yu, Ping
Li, Xin
Fu, Li
Xu, Huali
Sui, Dayun
Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
title Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
title_full Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
title_fullStr Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
title_full_unstemmed Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
title_short Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents Atherosclerosis in ApoE(−/−) Mice by Regulating PPARγ/FAK Signaling Pathway
title_sort ginsenoside rg3 alleviates ox-ldl induced endothelial dysfunction and prevents atherosclerosis in apoe(−/−) mice by regulating pparγ/fak signaling pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188907/
https://www.ncbi.nlm.nih.gov/pubmed/32390845
http://dx.doi.org/10.3389/fphar.2020.00500
work_keys_str_mv AT gengjianan ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT fuwenwen ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT yuxiaofeng ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT luzeyuan ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT liuyanzhe ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT sunmingyang ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT yuping ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT lixin ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT fuli ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT xuhuali ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway
AT suidayun ginsenosiderg3alleviatesoxldlinducedendothelialdysfunctionandpreventsatherosclerosisinapoemicebyregulatingppargfaksignalingpathway